Last reviewed · How we verify

BRC Operations Pty. Ltd. — Portfolio Competitive Intelligence Brief

BRC Operations Pty. Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Short Acting Methylphenidate Short Acting Methylphenidate marketed Sympathomimetic amine; CNS stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET) Neurology; Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Massachusetts General Hospital · 1 shared drug class
  3. NYU Langone Health · 1 shared drug class
  4. Novartis · 1 shared drug class
  5. Rhodes Pharmaceuticals, L.P. · 1 shared drug class
  6. Rochester Center for Behavioral Medicine · 1 shared drug class
  7. Rush University Medical Center · 1 shared drug class
  8. Seattle Children's Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BRC Operations Pty. Ltd.:

Cite this brief

Drug Landscape (2026). BRC Operations Pty. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/brc-operations-pty-ltd. Accessed 2026-05-15.

Related